Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine

Health Technology Assessment

Volumn 8, Issue 45, 2004, Pages

  Warren, E ^a   Weatherley Jones, E ^a   Chilcott, J ^a   Beverley, C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; IMMUNOSUPPRESSIVE AGENT; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LONG ACTING DRUG; METFORMIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLARGINE; GLYCOSYLATED HEMOGLOBIN; LONG ACTING INSULIN;

CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIABETES MELLITUS; DIARRHEA; DRUG COST; DRUG DELIVERY SYSTEM; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; ECONOMIC EVALUATION; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HUMAN; HYPOGLYCEMIA; INCIDENCE; INFORMATION PROCESSING; INJECTION SITE PAIN; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; JAUNDICE; LICENSING; MICROANGIOPATHY; MORBIDITY; MORTALITY; NATIONAL HEALTH SERVICE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET TRANSPLANTATION; PRACTICE GUIDELINE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; SENSITIVITY ANALYSIS; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT PLANNING; VOMITING; ADULT; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLASSIFICATION; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; FEMALE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; AGED; COST-BENEFIT ANALYSIS; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 9744219756     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta8450     Document Type: Review

References (61)

1. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva: WHO; 1999.
2. Gerich JE. Matching treatment to pathophysiology in type 2 diabetes. Clin Ther 2001;23:646-59.
3. DeFronzo RA, Reasner CA. Treatment of type 2 diabetes mellitus: a rational approach based on its pathophysiology. Am Fam Physician 2001; 63:1687-94.
4. Department of Health. Key features of a good diabetes service. Report No.: HSG(97)45. London: The Stationery Office; 1997.
5. Chief Medical Officer. The Annual Report of the Chief Medical Officer of the Department of Health for the Year 1997. London: The Stationery Office; 1998.
6. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14:s7-85.
7. Unwin N, Alberti KG, Bhopal R, Harland J, Watson W, White M. Comparison of the current WHO and new ADA criteria for the diagnosis of diabetes mellitus in three ethnic groups in the UK. Diabet Med 1998;15:554-7.
8. Chilcott JB, Wright J, Lloyd Jones M, Tappenden P. The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review. Health Technol Assess 2001;5(19).
9. Mackinnon M. Providing diabetes care in general practice. A practical guide for the primary care team. 3rd ed. Class Publishing: London; 1998.
10. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-8.
11. Eudra. Summary of product characteristics. 2002. URL: http://www.eudra.org/humandocs/humans/epar/lantus/lantus.htm
12. Nakhmanovich Y, Belenkaya R, Rozenfeld V. Insulin glargine in the management of diabetes mellitus. PPTTE 2001;26:176-81.
13. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000; 23:644-9.
14. Khan KS, Ter Riet G, Glanville J, Sowden AJ, Kleijnen J, for the NHS Centre for Reviews and Dissemination (CRD). Undertaking systematic reviews of research on effectiveness. CRD's guidance for carrying out or commissioning reviews. 2nd ed. CRD Report No. 4. York: NHS Centre for Reviews and Dissemination, University of York; 2002.
15. Jadad AR, Moore RA, Jenkinson C, Reynolds DJ, Cavaghan DJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clinl Trials 1996;17:1-12.
16. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
17. McKeage K, Goa KL. Insulin glargine: A review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs 2001;61:1599-624.
18. Gillies PS, Figgitt DP, Lamb HM. Insulin glargine. Drugs 2000;59:253-60.
19. Kelly JL, Hirsch IB. Insulin glargine: a review of its efficacy and safety in type 1 and type 2 diabetes. Today's Ther Trends 2001;19:85-91.
20. Information from the Aventis submission was submitted in confidence to NICE, 2002.
21. Aventis. Aventis submission to the National Institute of Clinical Excellence on the clinical and cost-effectiveness of insulin glargine (Lantus) for type 1 and 2 diabetes compared with other long and intermediate acting insulin preparations and insulin pump therapy. Aventis; 2002.
22. Rosenstock J, Park G, Zimmerman J, US Insulin Glargine (HOE). Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 2000; 23 1137-42.
23. Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care 2000;23:157-62.
24. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000;23:1666-71.
25. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. US Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2000;23:639-43.
26. Hershon K, Blevins T, Donley D, Littlejohn C. Beneficial effects of insulin glargine compared to NPH in subjects with type 1 diabetes. Diabetologia 2001;44:52.
27. Garg SK, Chase H, Marshall G. Plasma glucose profiles in patients with type 1 diabetes treated with insulin glargine or NPH insulin. Diabetes 2001;50: A435-6.
28. Garg S, Gerard L, Pennington M, Mecca T, Taylor L, Chase P, Jennings K. Efficacy of the new long acting insulin analog (HOE901) on fasting glucose values in IDDM. Diabetes 1998;47:1390.
29. Van Dyk J, HOE 901/3003 Study Group. Insulin glargine (HOE901) lowers fasting blood glucose in children with type 1 diabetes mellitus without increasing the risk of hypoglycaemia. J Pediatr Endocrinol Metab 2000;13(Suppl):34.
30. Matthews DR, Pfeiffer C. Comparative clinical trial of a new long-acting insulin (HOE901) vs. protamine insulin demonstrates less nocturnal hypoglycaemia. Diabetes 1998;47:394.
31. Raskin P, Park G, Zimmerman J. The effect of HOE 901 on glycemic control in type 2 diabetes. Diabetes 1998;47:404.
32. Rosenstock J, Schwartz SL, Clark CM, Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6.
33. Yki Jarvinen H, Dressler A, Ziemen M, HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-6.
34. Fonseca V, Bell D, Mecca T. Less symptomatic hypoglycemia with insulin glargine compared to NPH in patients with type 2 diabetes. Diabetologia 2001;44:796.
35. Talaulicar M, Willms B, Rosskamp R. HOE 901, a new insulin analogue, for substitution of basal insulin requirement in type I diabetes. Diabetes Stoffwechsel 1996;5:3-6.
36. Rosenstock J, Riddle M, Dailey G, Gerich J, Mecca T, Wilson C, et al. Treatment to target study: feasibility of achieving control with the addition of basal bedtime insulin glargine (Lantus® or NPH insulin in insulin-naive patients with type 2 diabetes on oral agents. Diabetes 2001;50:A129-30.
37. Pieber T, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 in patients with type 1 diabetes: a four-week randomised, NPH insulin-controlled trial. Diabetes 1998;47:242.
38. Pieber TR, Eugene Jolchine I, Derobert E. Efficacy and safety of HOE 901 in patients with type 1 diabetes: a four-week randomised, NPH insulin-controlled trial. Diabetologia 1998;41:187.
39. Hershon K, Blevins T, Donley D, Littlejohn C. Lower fasting blood glucose (FBG) and less symptomatic hypoglycemia with QD insulin glargine (Lantus®) compared to BID NPH in subjects with type 1 diabetes. Diabetes 2001;50:A116-17.
40. Fonseca V, Bell D, Mecca T. Less symptomatic hypoglycemia with bedtime insulin glargine (Lantus®) compared to bedtime NPH insulin in patients with type 2 diabetes. Diabetes 2001; 50:A112.
41. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996;313 275-83.
42. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002;324:705.
43. eBNF. 2002. URL: http://www.bnf.org/
44. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
45. 1c, risk of severe and mild hypoglycaemia, status of counterregulation and awareness of hypoglycaemia. Diabetologia 1996;39:677-86.
46. Mera RM, Bakst AW, Auland M. Independent predictors of quality of life in type 2 diabetes: the CODE-2 experience. Diabetes 2001;50:A77.
47. Stouthard MEA, Essink-Bot ML, Bonsel GJ. Disability weights for diseases in The Netherlands. Department of Health, Erasmus University, Rotterdam; 1997.
48. Nordfeldt S, Jonsson D. Short-term effects of severe hypoglycaemia in children and adolescents with type 1 diabetes. A cost-of-illness study. Acta Paediatr 2001;90:137-42.
49. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
50. Health Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
51. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
52. Delayed action insulins. What is the value of insulin glargine in general practice? (in German). MMW Fortschr Med 2001; 143:54-6.
53. Netten A, Rees T, Harrison G. Unit costs of health and social care 2001. University of Kent, Canterbury: Personal Social Research Unit (PSSRU); 2001.
54. Department of Health. HRG reference costs. 2002. URL: http://www.doh.gov.uk/nhsexec/refcosts/refcosts2001.pdf
55. The Diabetes Control and Complications Trial (DCCT) Research Group. Influence of intensive diabetes treatment on quality-of-life outcomes in the diabetes control and complications trial. Diabetes Care 1996;19:195-203.
56. de Grauw WJ, van de Lisdonk EH, van Gerwen WH, van den Hoogen HJ, van Weel C. Insulin therapy in poorly controlled type 2 diabetic patients: does it affect quality of life? Br J Gen Pract 2001; 51 527-32.
57. Irvine AA, Cox D, Gonder-Frederick L. Fear of hypoglycemia: relationship to physical and psychological symptoms in patients with insulin-dependent diabetes mellitus. Health Psychol 2002; 11 135-8.
58. Marrero DG, Guare JC, Vandagriff JL, Fineberg NS. Fear of hypoglycemia in the parents of children and adolescents with diabetes: maladaptive or healthy response? Diabetes Educator 1997;23 281-6.
59. Weinberger M, Kirkman MS, Samsa GP, Cowper PA, Shortliffe EA, Simel DL, et al. The relationship between glycemic control and health-related quality of life in patients with non-insulin-dependent diabetes mellitus. Medical Care 1994; 32:1173-81.
60. Costea M, Ionescu-Tirgoviste C, Cheta D, Mingu L. Fear of hypoglycaemia in type 1 (insulin-dependent) patients with diabetes. Rev Roum Med Int 1993;31:291-5.
61. Williams, G. Management of non-insulin-dependent diabetes mellitus. Lancet 1994; 343:95-100.